Nemaura Medical Inc logo

NMRD - Nemaura Medical Inc News Story

$4.12 -0.2  -4.6%

Last Trade - 06/12/21

Sector
Healthcare
Size
Small Cap
Market Cap £72.4m
Enterprise Value £70.8m
Revenue £n/a
Position in Universe 5512th / 7335

Nemaura Medical to Present at the LD Micro Main Event Conference

Tue 5th October, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211005:nGNXPLsyd&default-theme=true


Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.
(NASDAQ: NMRD), a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and supporting
personalized lifestyle coaching programs, announces today that Chief Executive
Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14(th) Annual
LD Micro Main Event Conference.

Dr. Chowdhury will deliver his corporate presentation on October 13 at 10:00
AM ET.

Register to watch the presentation here
(https://www.globenewswire.com/Tracker?data=w7oIJlcb6XRvDmGWfYuIIYUE_2vGCtph7BgnLr2Sv1tByqYxtqOnK-_l_CVam9Q0S1mAzbXrZru0ZiUy_Ylzcg==).

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and
commercializing non-invasive wearable diagnostic devices. The company is
currently commercializing sugarBEAT(®) and proBEAT(™). sugarBEAT(®), a CE
mark approved Class IIb medical device, is a non-invasive and flexible
continuous glucose monitor (CGM) providing actionable insights derived from
real time glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse, and prevent
the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval
Application) for sugarBEAT(®) to the U.S. FDA. proBEAT(™) combines
non-invasive glucose data processed using artificial intelligence and a
digital healthcare subscription service and has been launched in the U.S. as a
general wellness product as part of its BEAT(®)diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that
is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic
market, and the wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/3394c9a8-94b1-413d-aa55-0aa9d9f08641)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.